Welcome to our dedicated page for PMV Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 144 notice reporting a proposed sale of 2,283,654 shares of Common Stock through broker Themis Trading LLC with an approximate aggregate market value of $3,653,846.40. The filing lists the number of shares outstanding as 52,990,864 and gives an approximate sale date of 09/10/2025 on NASDAQ.
The securities were acquired on 09/29/2020 in the issuer's Initial Public Offering with cash payment. The filer certifies there were no securities sold in the past three months by the person for whose account the securities will be sold and represents they are unaware of any material nonpublic information about the issuer.
PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K reporting a material event: the company issued a press release and hosted an investor webinar on September 10, 2025 to present interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in multiple solid tumors with a TP53 Y220C mutation. The press release is attached as Exhibit 99.2 and is incorporated by reference into the filing.
The filing notes the public dissemination of clinical interim results and the webinar but does not include the data tables or numerical results within the 8-K text itself. No financial results, enrollment counts, regulatory actions, or next-step timelines are disclosed in the provided excerpt.
PMV Pharmaceuticals (PMVP) reports that Sio Capital Management, LLC beneficially owns 3,735,396 shares of common stock, equal to 7.19% of the class. The filing states Sio has shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, reflecting an adviser-managed position held for client funds.
The percentage is calculated using 51,952,680 shares outstanding as reported by the issuer. The filing notes Sio acts as investment adviser to affiliated funds that are the record owners and discloses that Sio GP, LLC and Michael Castor may be viewed as having influence, although any such beneficial ownership is expressly disclaimed. The statement also certifies the securities are held in the ordinary course of business and not to change or influence control.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 4 disclosing that General Counsel & COO Robert Ticktin sold 23,151 common shares on 1 July 2025 at an average price of $1.0648 per share.
The filing states the shares were withheld for tax obligations arising from the vesting of restricted stock units (RSUs). Following the transaction, Ticktin retains 98,695 shares of PMVP, which include 15,528 shares purchased under the company’s Employee Stock Purchase Plan on 15 May 2025. No derivative security transactions were reported.
The sale represents a disposition of approximately 19% of his prior directly held shares; however, because the purpose is tax-related rather than discretionary, the market signal is typically viewed as neutral.
PMV Pharmaceuticals (PMVP) – Form 4 insider transaction
Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.
PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction
President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).
After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.
The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.